GlassScriptPhysician profile
Geover Fernandez
NPI 1639103138
$14,079.07
in general payments reported to CMS, 2019-2025
44 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 85% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,962 · 2020: $388 · 2021: $601 · 2022: $1,169 · 2023: $1,585 · 2024: $1,688 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,799 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,798.55 |
| Education | $161.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,311.57 | 2019 | |
| Abbvie INC. | $2,283.35 | 2019-2025 | |
| Janssen Biotech, INC. | $749.79 | 2019-2025 | Tremfya |
| Amgen INC. | $652.68 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $550.70 | 2019-2025 | |
| Genzyme Corporation | $486.19 | 2019-2025 | |
| Incyte Corporation | $471.68 | 2022-2025 | Opzelura, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $414.01 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $306.02 | 2019-2025 | Winlevi |
| Ucb, INC. | $239.37 | 2019-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $233.96 | 2019 | |
| Pfizer INC. | $229.68 | 2019-2023 | |
| Leo Pharma INC. | $220.92 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $161.68 | 2019-2025 | Dupixent |
| Smith+Nephew, INC. | $150.37 | 2022-2025 | Grafix Pl |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $147.99 | 2024 | |
| Biofrontera INC. | $125.01 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $110.89 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.35 | 2019-2023 | Siliq |
| Octapharma USA, INC. | $106.94 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $103.89 | 2021-2024 | Valchlor |
| Lilly USA, LLC | $101.02 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $87.62 | 2024-2025 | Zoryve |
| Seagen INC. | $84.86 | 2020-2023 | Tukysa |
| Organogenesis INC. | $64.82 | 2024-2025 | Simplimax, Puraply Wound Matrix, Cygnus Dual |
| Exelixis INC. | $55.05 | 2021-2023 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.69 | 2023-2024 | Spevigo |
| Jazz Pharmaceuticals INC. | $47.95 | 2020-2021 | |
| Eisai INC. | $44.49 | 2020-2021 | |
| Glaxosmithkline, LLC. | $42.75 | 2020 | |
| Dendreon Pharmaceuticals LLC | $41.91 | 2019-2021 | |
| Genentech USA, INC. | $37.78 | 2022 | |
| Tesaro, INC. | $33.49 | 2019 | |
| Botanix Sb INC | $27.85 | 2025 | Sofdra |
| Stimlabs LLC | $26.34 | 2025 | Corplex P |
| Takeda Pharmaceuticals U.S.A., INC. | $22.96 | 2021 | |
| Kyowa Kirin, INC. | $22.80 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.81 | 2024 | Qinlock |
| Dermavant Sciences, INC. | $19.78 | 2023 | Vtama |
| Dusa Pharmaceuticals, INC. | $19.53 | 2019 | |
| Morphosys, US INC. | $17.86 | 2021 | |
| Puma Biotechnology, INC. | $17.14 | 2019 | |
| Daiichi Sankyo INC. | $16.65 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geover Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.